Studies show that there are few if any, additional side effects from the COVID-19 vaccine for people with eczema. In one ...

Analysts predict peak annual sales of around $2.5 billion for Dupixent, which the FDA approved in March last year for eczema – known ... because it is also an injection. Patients may opt to ...

Sanofi has upped its revenue forecasts for the year on the back of strong second quarter results from its new eczema and asthma injection Dupixent and its rare diseases and vaccines businesses.

The study met its primary endpoint, but analysts compared the results unfavorably to the data on Dupixent. Adjusted for placebo, 19.1% of people on rocatinlimab had 75% improvement in eczema area ...